The global long read sequencing sector is expanding rapidly as researchers, healthcare providers, and biotechnology companies adopt advanced genomic technologies. The sector is estimated at USD 1.34 billion in 2026 and is projected to reach USD 15.14 billion by 2035, growing at a CAGR of 30.96% from 2026 to 2035.
What Is Long Read Sequencing?
Long-read sequencing (LRS) is an advanced DNA sequencing technology that reads much longer DNA fragments than conventional short-read methods. It helps researchers identify structural variations, complex mutations, repetitive sequences, and other genomic changes that can be difficult to detect using traditional techniques.
Growing genetic disorders, rising demand for personalized medicine, and advances in genomics research are supporting wider adoption of LRS technology.
Key Trends Driving Growth
One of the major trends is the increasing use of long-read sequencing in whole genome sequencing, rare disease research, cancer genomics, personalized medicine, transcriptomics, and metagenomics.
Nanopore sequencing led the technology segment with a 58% share in 2025, supported by real-time analysis capabilities and flexible applications. Single-molecule real-time sequencing is also expected to experience significant growth as researchers seek highly accurate genomic analysis.
By product, consumables accounted for 48% of the share in 2025, while sequencing represented 55% of the workflow segment. Whole genome sequencing led applications with a 35% share.
Regional Outlook
North America held a 43% share in 2025, supported by advanced research infrastructure, strong investments, leading sequencing companies, and growing precision medicine initiatives.
Asia Pacific is expected to record the fastest growth, driven by expanding genomics programs, biotechnology investments, and government-supported research initiatives in countries including China and India.
Opportunities and Challenges
The growing adoption of precision medicine presents significant opportunities for long-read sequencing. Its ability to identify complex genetic variations can support rare disease diagnosis, cancer research, infectious disease studies, and drug development.
However, high costs and accuracy limitations compared with some short-read technologies remain key challenges. Continued technological improvements could help make LRS more accessible to researchers and healthcare organizations.
Download a Sample Report: https://www.towardshealthcare.com/download-sample/5324
Future Outlook
Long-read sequencing is becoming an important technology for next-generation genomics. As sequencing platforms become more accurate, scalable, and affordable, applications across healthcare, biotechnology, and research are expected to expand significantly through 2035.
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium